POLYMACROCYCLIC PEPTIDES - Engineering Structure for Function in Next Generation Therapeutics
Karsten Eastman, PhD, and Vahe Bandarian, PhD, believe the key challenge, and opportunity, is to sculpt peptide architecture so that shape and chemistry are presented to the target in the right place, at the right time, and for long enough to matter clinically.
TECHNOLOGY TRANSFER - Streamlining Biologics Technology Transfer Through Integrated Operational Models
Lalit Saxena explains how technology transfer in biologics manufacturing is an inherently complex process that requires the simultaneous control of multiple scientific, technical, and operational variables.
EXECUTIVE INTERVIEW - Lonza: Addressing Solubility Challenges in Early Stages of Drug Development
Adi Kaushal, Director and Technology Head, Bioavailability Enhancement, at Lonza, discusses solubility issues and Lonza’s approach to addressing these challenges in the early stages of drug development.
THERAPEUTIC FOCUS - Advancing Adjunctive Therapies for Depression & OCD Using Translational Pharmaceutics®
Jacob Jacobsen, PhD, Bret Berner, PhD, and Vanessa Zann, PhD, review a partnership with Evecxia Therapeutics to support the development of EVX-101, an investigational adjunctive drug for depression and obsessive-compulsive disorder (OCD) responding inadequately to first-line antidepressants.
RADIOLIGAND THERAPIES - Affibody Molecules: A Versatile Approach to Radiopharma
Fredrik Frejd reviews Affibody’s lead RLT candidate, ABY-271, currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.
SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
Contributor Cindy H. Dubin speaks with leading drug makers, device manufacturers, and contract organizations who dispel the myths around AI and Machine Learning in the pharma industry and share how they are using AI to streamline clinical trials, automate lab tests, optimize resource allocation, enhance development timelines, and improve patient-friendly dosage forms.
FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, review a few examples of controlled release excipients and their attributes from monolithic matrix tablets and polymeric coated tablets.
LEADERSHIP PANEL - Trends to Watch for in 2026
Contributor Cindy H. Dubin interviews life science leaders to discuss the role of AI in drug repurposing, the future of personalized medicine, the importance of sustainability, and how to keep pace with innovation amid real-time FDA reviews.
PREFILLABLE SYRINGE SYSTEM - Beyond Components: Designing Prefillable Syringe Systems to Streamline Success
Katie Falcone says prefillable syringes for biologics and vaccines can no longer be assembled as a set of parts; they must be treated as engineered systems with data, supply, and regulatory strategies built in from the start.
CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
True Rogers, RPh, PhD, Matthias Knarr, PhD, and Mark Dreibelbis, PhD, say excipient selection is a key consideration within the QbD framework, particularly for CR technologies. Excipients must be chosen carefully to ensure they deliver the needed processability, quality, stability, and performance during and following the manufacture of dosage forms.
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
Dikla Czaczkes Akselbrad asks what if, instead of relying on systemic delivery, a platform could be created that anchors drugs directly at the site of need and controls its release over weeks or months?
MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
Nandkumar Deorkar, PhD, explores some of the key challenges in mAb formulation and fill-finish, offering practical insights to help developers navigate complexity and ensure success.
EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
Chris Ehrlich, CEO of CERo Therapeutics, discusses the company’s science, clinical program, the treatment landscape, and more.
Expert Insights Videos
Go beyond the written word with our new podcast series, featuring in-depth conversations with industry leaders shaping the future of drug development and delivery. Each episode explores real-world challenges, emerging technologies, and the insights driving innovation across the pharmaceutical landscape.
Better Bioavailability Faster Timelines with Ascendia Pharmaceutical Solutions
In the rapidly evolving world of pharmaceuticals, understanding the intricacies of drug development is essential for anyone interested in healthcare innovation. In this episode of…
2026 Drug Development Outlook: What Industry Insiders Are Saying
In this new interview, veteran pharma journalist Cindy H. Dubin reveals the real shifts leaders are betting on for 2026: AI completely changing how drugs…
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Executive Interview: Advancing Regenerative Medicine for Chronic Disease
Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.
eBook: Understanding the Foundation of LNP Formulation Success
Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve
Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.
Biocatalysis Without Barriers for Efficient Small Molecule Process Development
As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.
VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development
In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.
Have expert content to share? Contact us
WHITEPAPERS & WEBINARS
WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
This article explores how AI-driven predictive insights reduce uncertainty in early oral drug development, enabling smarter decisions on solubility, dosing, stability, and scale-up while preserving API, accelerating timelines, and de-risking clinical success .
WHITE PAPER - Small Molecules: Choosing the Right Development Path
This white paper outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
WHITE PAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford, review how for many high-potency APIs, micronization is not a downstream convenience but a critical performance step. Particle size distribution directly influences dissolution behavior, bioavailability, blend uniformity, and dose accuracy, particularly when therapeutic doses are measured in micrograms.
WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as the Mantoux technique with modern innovations such as the Terumo Immucise™ Intradermal Injection System.
WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled.
WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine
Enabling technologies such as Nanotechnology, Amorphous Solid Dispersions, Self-emulsifying/nanoemulsifying drug delivery systems (SEDDS/SNEDDS) or Lipid Nano Particles (LNPs) for oral delivery are key elements for the development of complex and difficult to develop small molecules.
ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing
Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological fields, the white paper provides essential insights into how advanced in vitro skin and mucosal tissue systems are reshaping research and development practices.
MARKET NEWS & TRENDS
Bio-Rad Extends Range of Anti-Idiotypic Antibodies & Anti-Fc Mutation Antibodies for Bioanalysis & Drug Monitoring
Bio-Rad Laboratories, Inc. recently extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab…
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head & Neck Cancer
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization…
PannTheraPi Announces Significant Clinical Development & Strategic Milestones
PannTheraPi recently announced significant progress in its clinical development alongside a key leadership appointment to strengthen its scientific and operational capabilities. The company has submitted…
ProImmune Collaborates With The University of Texas Medical Branch to Advance Infectious Disease Research
ProImmune, Ltd.recently announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop…
Symbiosis Expands Commercial Capabilities With Addition of New Stability Chamber
Symbiosis Pharmaceutical Services has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber. This addition enables Symbiosis to replicate…
Vetter Strengthens its Global Clinical Manufacturing Network With Strategic Site Enhancements
Vetter recently announced significant progress in the continued expansion of its global clinical manufacturing network. With the ongoing scale-up of its Vetter Development Service offering,…
Alzheon Advances Next-Gen Pipeline With First Patient Dosed in ALZ-507 Study
Alzheon, Inc. recently announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of…
Cereno Scientific Reports Robust Safety & Tolerability in Long‑Term CS1 Pulmonary Arterial Hypertension Study
Cereno Scientific provides additional context on the safety and tolerability data from up to 12 months of treatment from the Expanded Access Program (EAP) with…
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals, Inc. recently announced publication of the results from the NEW DAY clinical trial involving ILUVIEN (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for…
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics, a registration-stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA)…
Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Adragos Pharma recently announced it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of…
Cyclerion Therapeutics & Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. recently announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the…
Amprion Grows Global Footprint With Australian Partnership & Expanded Research Collaborations
Amprion recently announced a series of strategic milestones that underscore the company’s accelerating growth, expanding international footprint, and continued commitment to advancing earlier and more accurate…
Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility
Samsung Biologics recently announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in…
PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS
A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery – current cell models used for testing treatments do…
Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer
Symeres has recently partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class of small molecules, known as molecular glues, for potential…
ImmuneOncia Therapeutics & Lonza Collaborate to Manufacture a PD-L1 Antibody Targeting Immuno-Oncology
ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today…
Vetter Recognized as 2026 CDMO Leadership Awards Winner
Vetter receives recognition as CDMO of the year in the category “Finished Dose” of the 2026 CDMO Leadership Awards. The award honors the company for…
Thermo Fisher Scientific & SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions
Thermo Fisher Scientific Inc. recently announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile…
Optibrium Introduces Graphical Interface for QuanSA to Enhance Ligand-Based Affinity Predictions
Optibrium recently announced a new QuanSA plugin for PyMOL, providing an intuitive Graphical User Interface (GUI) for its ligand-based binding affinity prediction method, part of…
